The global vaccine market size is anticipated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising awareness of vaccination and high demand for better healthcare infrastructure.
Vaccines are also called as immunizations. Vaccine is an attenuated form of an infective organism, which is injected to a person to enhance immunity or antibodies against the disease. The use of vaccination has eliminated the chance of developing a number of diseases and even eradicated some of diseases such as smallpox and polio. Immunization plays a vital role to increase the quality of life of people by providing protection against various disease. The demand for immunization gained significant demand over the recent years, which is attributed to rise in prevalence of both bacterial and viral infectious diseases. Vaccinations are injected to people of various age groups, which brace the immune system for complete life span as well as provide protection against several infectious diseases.
As per several research studies, vaccination has prevented around 2 million people from succumbed to different diseases such as measles, tetanus, influenza, pertussis, diphtheria, and others. Additionally, according to the World Health Organization (WHO), more than 1.5 million deaths are estimated to be possible to be prevented, due to the advancement in global immunization coverage.
The COVID-19 pandemic outbreak caused most of the pharmaceutical, biotechnology, and healthcare organizations to focus on safety wearable, diagnostics kits, vaccines, and drugs for Novel coronavirus treatment. The major players in the market started to concentrate on developing vaccine for coronavirus. Furthermore, the healthcare professionals are busy in COVID-19 related services. The pharmaceutical organizations are focusing on research & development of COVID-19 related vaccines, treatments, diagnostics, and health technologies. All these factors are expected to drive the global vaccines market during the forecast period.
The report on the global vaccine market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Vaccine Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Types (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines, Conjugate Vaccines, and Subunit Vaccines) and Applications (Infectious Diseases, Cancer, Autism, and Allergy) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Merck &Co., Inc.; Emergent BioSolutions, Inc.; Johnson and Johnson; Sanofi Pasteur, Inc.; Pfizer, Inc.; Novartis AG; CSL Ltd.; GlaxoSmithKline Plc.; Abbott Laboratories, Inc.; AstraZeneca Plc; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals Company Ltd.; and Valeant Pharmaceuticals International, Inc. |
Based on the types, the global vaccine market is divided into live toxoid vaccines, attenuated vaccines, inactivated vaccines, DNA vaccines, conjugate vaccines, and subunit vaccines. The inactivated vaccines segment is expected to exhibit substantial growth during the projected period owing to the great stability and long shelf-life with high efficacy of the vaccine type. However, the DNA vaccine segment is expected to grow at an impressive growth rate in the coming years due to its reduced risk of integration and high specificity. The development of different vaccines and its high demand as well as various drugs under the pipeline are bolstering the market segment.
On the basis of applications, the market is segregated into infectious diseases, cancer, autism, and allergy. The infectious disease segment is projected to expand at a considerable CAGR during the forecast period attributed to high prevalence of infectious diseases and rising concerns about the vaccination among the population. Moreover, high frequency of diseases such as hepatitis, cholera, chickenpox, measles, typhoid, and others are major factors for this segment development. The extensive research activities for the disease control and prevention has resulted into large number of potential candidates for vaccine. The COVID-19 has also boosted the segment as many companies invested hugely for this vaccine development.
Cancer segment, however, is anticipated to register a substantial growth rate during the projected period as cancer is highly prevalent disease globally. As per several reports from organizations such as WHO, the number of the population suffering from cancer is going to increase continuously in the future.
In terms of regions, the global vaccine market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share in the coming years owing to the well-developed healthcare infrastructure as well as presence of skilled professionals in the region. Moreover, huge investment by some of the major market players in the region is boosting the regional market expansion.
The market of Asia Pacific, however, is anticipated to grow at a robust pace in the forecast period attributed to the presence of a large number of untapped population in the region. Furthermore, growing disposable income and increasing awareness about the vaccine benefits among a huge population group in the region are estimated to spur the regional market expansion in the coming future.
The key players of the global vaccine market are Merck &Co., Inc.; Emergent BioSolutions, Inc.; Johnson and Johnson; Sanofi Pasteur, Inc.; Pfizer, Inc.; Novartis AG; CSL Ltd.; GlaxoSmithKline Plc.; Abbott Laboratories, Inc.; AstraZeneca Plc; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals Company Ltd.; and Valeant Pharmaceuticals International, Inc. AstraZeneca collaborated with the University of Oxford to develop the COVID-19 vaccine in 2020 in an attempt to curb the spread of the pandemic.
Some other reports from this category!